Silence Therapeutics (SLN) Non-Current Deffered Revenue (2019 - 2026)

Silence Therapeutics has disclosed Non-Current Deffered Revenue across 8 years of filings, most recently posting $55.2 million for Q1 2026.

• Non-Current Deffered Revenue for Q1 2026 came in at $55.2 million, up 3.62% year-over-year; the trailing twelve-month figure through Mar 2026 was $55.2 million (up 3.62% YoY), and the FY2025 annual result was $55.5 million, up 7.07% from the prior year.
• Non-Current Deffered Revenue came in at $55.2 million for Q1 2026 at Silence Therapeutics, roughly flat from $55.5 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $74.5 million in Q4 2022 to a low of $51.8 million in Q4 2024.
• The 5-year median for Non-Current Deffered Revenue is $55.4 million (2025), against an average of $59.4 million.
• Across the five-year window, Non-Current Deffered Revenue dropped 29.17% in 2024 and gained 7.07% in 2025, its largest moves.
• Silence Therapeutics' Non-Current Deffered Revenue stood at $74.5 million in 2022, then decreased by 1.81% to $73.1 million in 2023, then decreased by 29.17% to $51.8 million in 2024, then increased by 7.07% to $55.5 million in 2025, then dropped by 0.43% to $55.2 million in 2026.
• The last three Non-Current Deffered Revenue figures came in at $55.2 million (Q1 2026), $55.5 million (Q4 2025), and $55.3 million (Q3 2025), per Business Quant data.